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Summary
 
Peripheral lymph nodes (PLN) are critical for immunologic memory formation in response to
antigens that penetrate the skin. Blood-borne lymphocytes first encounter such antigens after
they home to PLN through a multi-step adhesion process that is normally initiated by L-selec-
tin (CD62L) in high endothelial venules (HEV). Since naive T cells can not enter PLN nor-
mally in L-selectin–deficient mice, a delayed type hypersensitivity response to cutaneously ap-
plied antigen cannot be mounted. In this study, we report that the administration of activated
platelets into the systemic circulation of L-selectin knockout mice restores lymphocyte traffick-
ing to PLN, and reconstitutes T cell–mediated immunity in response to a cutaneous antigen.
These effects required platelet-expressed P-selectin that allows activated platelets to transiently
form a bridge between lymphocytes and HEV, thereby enabling lymphocytes to undergo sub-
sequent 
 
b
 
2 integrin-dependent firm adhesion. These profound effects of platelet-mediated
cell–cell interactions on lymphocyte trafficking and formation of immunologic memory may
impact on a variety of autoimmune and inflammatory conditions.
 
I
 
mmunocompetent lymphocytes continuously patrol the
body in search of foreign antigen (1). To effectively do
this, a sequence of critical adhesion events that allows these
cells to migrate from the circulation into tissues must oc-
cur. In peripheral lymph nodes (PLN), the interaction of
the lymph node homing receptor, L-selectin (CD62L), with
its counterreceptor expressed on high endothelial venules
(HEV), the peripheral node addressin (PNAd), is the first
essential step in the extravasation of immunologically naive
lymphocytes (2–4). L-selectin–PNAd interaction mediates
the tethering and rolling of most lymphocytes in HEV, but
is not sufficient by itself for lymphocyte emigration (5).
The rolling cells must first encounter an activating stimulus
that transmits a G protein–dependent transmembrane signal
and triggers stationary adhesion through functional upregu-
lation of the 
 
b
 
2 integrin LFA-1 (6). The importance of
L-selectin as the physiologic initiator of this adhesion cas-
cade is best exemplified by the inability of naive T cells to
home to PLN in L-selectin–deficient mice (7, 8). In fact,
the lack of T cell trafficking through PLN in these animals
was shown to be responsible for the inability to elicit a con-
tact hypersensitivity (CHS) immune response by cutaneous
exposure to a hapten antigen (7, 9).
In addition to L-selectin, circulating activated platelets
can provide a second mechanism for initiating lymphocyte
interactions with the HEV of PLN (10). P-selectin (CD62P)
expressed on activated platelets can mediate adhesion to both
lymphocytes and HEV via interactions with P-selectin gly-
coprotein ligand 1 (PSGL-1) and PNAd, respectively, re-
sulting in sustained rolling of lymphocyte–platelet aggre-
gates even in the absence of functional L-selectin. In this
study, we have set out to examine the functional signifi-
cance of this platelet-mediated lymphocyte delivery to
HEV. We tested whether rolling promoted by this alterna-
tive adhesion pathway is sufficient to reestablish lympho-
cyte trafficking in L-selectin–deficient mice and whether
lymphocytes delivered in this manner to PLN were capable
of participating in a CHS immune reaction. We found that
lymphocytes delivered by platelets could indeed accumu-
late and extravasate in PLN–HEV. L-selectin–deficient lym-
phocytes homed to PLN via a multi-step adhesive process
that was initiated by platelet P-selectin and was followed by
activation of rolling lymphocytes that arrested via engage-
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Abbreviations used in this paper:
 
 CHS, contact hypersensitivity; DNBS,
2,4-dinitro-benzene sulfonic acid; DNFB, 2,4-dinitrofluorobenzene;
HEV, high endothelial venules; PLN, peripheral lymph nodes; PNAd,
peripheral node addressin; PSGL-1, P-selectin glycoprotein ligand 1;
TRAP, thrombin receptor-activating peptide; WBC, white blood cell.
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ment of LFA-1. Importantly, a transfusion of activated
platelets 1 d after cutaneous sensitization of L-selectin–defi-
cient mice normalized the CHS response in these animals,
suggesting that platelet-delivered T cells were immuno-
competent and could efficiently detect and respond to anti-
gen presented in PLN.
 
Materials and Methods
 
Antibodies.
 
Function blocking anti–murine L-selectin mAb
Mel-14, anti–murine LFA-1 (CD11a) mAb TIB 213, and anti–
human P-selectin mAb WAPS 12.2 were provided by Dr. E.C.
Butcher (Stanford University, Stanford, CA). Anti–human CD41
mAb 7E3 was a gift of Dr. B. Coller (Mt. Sinai Medical Center,
New York). FITC-conjugated mAbs to murine TCR
 
a
 
/
 
b
 
, Mac-1
(CD11b), and anti-B220, and PE-conjugated nonblocking anti–
human P-selectin (mAb S12) were purchased from PharMingen (San
Diego, CA) and Becton-Dickinson (San Jose, CA), respectively.
Anti–human CD31 mAb Hec 7 and unlabeled anti–human P-selec-
tin mAb S12 were gifts of Drs. W.A. Muller (The Rockefeller Uni-
versity, New York) and R.P. McEver (University of Oklahoma
Health Sciences Center, Oklahoma City, OK), respectively. Non-
binding isotype-matched antibodies were used as negative controls.
 
Intravital Microscopy.
 
Mice were anesthetized and catheter-
ized, and the left subiliac LN was microsurgically prepared as pre-
viously described (5). Human platelets were isolated from blood
of healthy donors following established procedures (11). For mi-
croscopic visualization of endogenous white blood cell (WBC)
interactions with vascular endothelium, a bolus injection of saline
(10 ml/kg body weight) containing 1 mg/ml of the nuclear dye
Rhodamine 6G (Molecular Probes, Inc., Eugene, OR) was given
intravenously. Interacting and freely flowing blood-borne WBCs
were videotaped during their passage through LN HEV under
fluorescent stroboscopic epi-illumination and observation through a
 
3
 
40 Zeiss objective (Achroplan, numerical aperture 0.75 
 
¥
 
, wa-
ter; Carl Zeiss, Inc., Thornwood, NY). The rolling fraction, de-
fined as the percentage of interacting WBCs in the total number
of fluorescent cells passing through a venule during 3 min, was
determined by off-line analysis of video recordings. The sticking
fraction, defined as the percentage of rolling WBCs that became
stationary for a minimum of 30 s, was determined during the
same period. After an initial observation period to establish base-
line interactions, some animals were injected with 3 boluses (200 
 
m
 
l
each at 2 min intervals) of resting or TRAP (thrombin receptor
activating peptide)-activated human platelets (2 
 
3
 
 10
 
8
 
/ml), and
WBC behavior was recorded in the same vascular bed. Some ali-
quots of activated platelets were pretreated with mAb WAPS12.2
(20 
 
m
 
g/ml) before injection. In some experiments, platelets were
fluorescently labeled with 2
 
9
 
7
 
9
 
,-bis-(2-carboxyethyl)-5(and 6)
carboxyfluorescein (Molecular Probes, Inc.) to distinguish WBCs
and injected platelets as previously described (10). To test the role
of L-selectin and LFA-1 in HEV, some animals were treated with
a 300 
 
m
 
l bolus of saline containing 100 
 
m
 
g of mAb Mel-14 or
mAb TIB 213, and WBC adhesion before and after injection of
activated platelets was analyzed.
 
Flow Cytometry and Platelet-PBMC Aggregation Assay.
 
Murine
PBMCs were isolated by density gradient centrifugation using lym-
pholyte-M (Accurate Chemical and Science Corp., Westbury, New
York), washed in PBS with 1% heat-inactivated human serum albu-
min (HSA) and 5 mM EDTA, pH 7.4 (PBE) and subsequently
resuspended in HBSS containing 10 mM Hepes, 2 mM CaCl
 
2
 
, and
0.2% HSA, pH 7.4 (assay media).
Purified PBMCs (2 
 
3
 
 10
 
6
 
/ml) in PBE were preincubated at
4
 
8
 
C for 30 min with FITC-conjugated antibodies that recognize
murine Mac-1, TCR-
 
a
 
/
 
b
 
, or B220. TRAP-activated human
platelets (10
 
8
 
/ml) were labeled with nonblocking PE-conjugated
mAb S12 to human P-selectin. Stained cells were washed twice
and resuspended in assay media. 50 
 
m
 
l each of platelets and PBMCs
were subsequently coincubated in microtiter wells at 4
 
8
 
C for 1 h.
In some experiments, labeled platelets were pretreated for 30 min
with 20 
 
m
 
g/ml P-selectin mAb WAPS 12.2 (which blocks the lec-
tin domain) or nonblocking control mAb S12 (which recognizes
the SCR domain) and subsequently mixed with the PBMC sus-
pension without washing. The two mAbs do not interfere with
each other’s binding to P-selectin (Diacovo, T.Y., and U.H. von
Andrian, unpublished data). Platelet adhesion to PBMCs was quan-
titated by measuring red and green fluorescence on a FACScan
 
Ò
 
flow cytometer (Becton Dickinson, San Jose, CA). Gating on
events identified by light scatter as lymphocytes or monocytes
was performed to exclude single platelets. For each experiment, a
sample containing either labeled platelets mixed with unlabeled
PBMCs or labeled PBMCs alone was used to set threshold mark-
ers on the red and green fluorescence scale, respectively. MAb-
labeled PBMCs showing the platelet marker were interpreted as
cells that bound platelets. Results are presented as percentage of
platelet-bound PBMCs expressing Mac-1, TCR-
 
a
 
/
 
b
 
, or B220 in
the total number of cells in the same subset.
 
Elicitation of CHS Response.
 
A cutaneous delayed type hyper-
sensitivity immune response was induced by application of 0.5%
2,4-dinitrofluorobenzene (DNFB) in acetone/olive oil (4:1) on
the shaved abdomina of mice as previously described (7). 18 h after
sensitization, mice were anesthetized, the right external jugular
vein was cannulated, and a total volume of 3 ml of TRAP-acti-
vated human platelets (10
 
8
 
/ml) were administered intravenously
over 6 h as repeated small boluses. Activation status of platelets
was confirmed by flow cytometry of P-selectin expression. For
antibody inhibition studies, platelets and mice were pretreated
with function blocking antibodies (50 
 
m
 
g/ml and 100 
 
m
 
g/mouse,
respectively) to human P-selectin (mAb WAPS 12.2) or human
CD31 (mAb Hec 7). Mice were rechallenged with 0.25% of
DNFB on the left pinna (10 
 
m
 
l) on day 5, and ear swelling re-
sponses were measured 24 h after elicitation. Subsequently, the
animals were killed and lymphocytes pooled from cervical, subil-
iac, and axillary nodes were counted on a hemocytometer.
 
In Vitro Lymphocyte Proliferation Assay.
 
For analysis of anti-
gen-specific T cells in the PLN of mice, nodes were harvested 5 d
after DNFB sensitization of mice with and without infusion of
platelets and antibodies as described above. Isolated lymphocytes
(2 
 
3
 
 10
 
4
 
–1.6 
 
3
 
 10
 
5
 
 cells) were cultured for 36 h in triplicate in
the presence or absence of DNBS, the water soluble form of DNFB
(50 
 
m
 
g/ml), and then pulsed with 1 
 
m
 
Ci/well of [
 
3
 
H]thymidine
for 18 h before harvesting cells as previously described (7).
 
Statistical Methods.
 
Where appropriate, data are presented as
the arithmetic mean 
 
6
 
 1 SD. A statistical analysis of the ear swell-
ing response was performed using the Kruskal-Wallis test for one-
way analysis of variance followed by multiple comparisons on
ranks using the Bonferroni correction of 
 
P.
 
 Results were consid-
ered statistically significant when 
 
P
 
 
 
,
 
0.05.
 
Results
 
Activated Platelets Promote Lymphocyte Rolling in PLN–
HEV of L-selectin–deficient Mice.
 
The behavior of rhodamine
6G–labeled circulating WBCs in PLN–HEV of L-selectin– 
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deficient mice was evaluated using intravital microscopy
(5). In agreement with previous studies using a neutralizing
antibody to L-selectin (10), the rolling fraction of WBCs in
mice lacking this homing receptor (12.1 
 
6
 
 5.3%, mean 
 
6
 
SD) was considerably reduced in comparison to that in
wild-type littermates (72.1 
 
6
 
 12.1%; Figs. 1 and 2 
 
a
 
). In-
jection of activated, but not resting, human platelets en-
hanced leukocyte rolling in the HEV of mutant mice (roll-
ing fraction of 48.9 
 
6
 
 9.6%), approaching a level similar to
that seen in wild-type mice. The pivotal role of platelet
P-selectin was confirmed by the ability of mAb WAPS
12.2, directed against human, but not murine, P-selectin,
to abolish this effect.
 
Lymphocytes Delivered by Platelets Firmly Adhere to HEV
via LFA-1.
 
Although selectin binding to PNAd is highly
efficient at initiating rolling interactions in flow, in vitro
studies indicate that engagement of additional adhesion re-
ceptors is required for lymphocyte arrest in HEV (12).
Indeed, recent in vivo experiments have shown that L-selec-
tin–dependent lymphocyte rolling is followed by an activa-
tion–dependent arrest mediated by LFA-1 (6). We hypoth-
esized that in order for L-selectin–deficient lymphocytes to
accumulate in tissues where PNAd is expressed, a similar
sequence of events must occur to stabilize dynamic interac-
tions initiated by platelet P-selectin. Infusion of activated
platelets in L-selectin–deficient mice not only restored roll-
ing, but 
 
.
 
50% of interacting WBCs became stably adher-
ent to HEV, and a large fraction of stuck cells eventually
transmigrated (Fig. 2, 
 
b
 
 and 
 
c
 
). Since both WBCs and plate-
lets express several integrin receptors that are capable of
strengthening adhesive interactions with vascular endothe-
lial cells, mutant mice or platelets were treated with func-
tion-blocking mAb to LFA-1 (TIB 213) or to CD41 (7E3)
before platelet injection. MAb TIB 213, but not mAb 7E3,
reduced leukocyte sticking by 
 
z
 
90%; neither had any ef-
fect on rolling (Figs. 1 and 2 
 
d
 
 and data not shown). Since
human platelets do not express 
 
b
 
2-integrins and TIB 213
binds only murine, but not human LFA-1 (reference 13 and
our unpublished data), these results demonstrate that the
sticking of WBC–platelet aggregates was mediated by LFA-1
on WBCs. Therefore, the cellular bridge between lympho-
cytes and HEV that was initially created by platelets al-
lowed for a critical period of exposure of lymphocytes to
chemoattractant signals on HEV that was sufficient to acti-
Figure 1. Effect of circulating, activated platelets on WBCs rolling in
PLN–HEV of mice deficient in L-selectin. WBCs (mononuclear cells and
granulocytes) were fluorescently labeled in situ with rhodamine 6G, visu-
alized in HEVs of PLN of wild-type (closed bars) and L-selectin–deficient
(open bars) mice by fluorescence intravital microscopy, and rolling frac-
tions quantitated as previously described (10). The effect of mAbs and
platelet injections on the WBC rolling fraction was determined in identi-
cal fields of view. The L-selectin blocking mAb Mel-14 was tested in 10
venules of 4 wild-type animals. The ability of platelets to reconstitute roll-
ing in mutant animals was examined by injecting TRAP-activated or rest-
ing, human platelets (12 venules in 5 animals). The ability of the human
P-selectin mAb WAPS 12.2 and murine LFA-1 mAb TIB 213 to inhibit
WBC rolling was also evaluated (four venules in three animals each). Data
are shown as mean 6 SD.
Figure 2. Activated human platelets support WBCs homing to subiliac PLN in L-selectin–deficient mice. WBCs were fluorescently labeled in situ us-
ing rhodamine 6G and recorded during their passage through single HEV. (A) Digitized intravital fluorescence micrograph of a typical HEV in an L-selec-
tin–deficient mouse. Relatively few blood-borne cells (arrows) interacted with the vascular wall over a 45-min control period (0 min). (B) Intraarterial in-
jection of TRAP-stimulated human platelets over a 10-min period resulted in rolling and accumulation of sticking endogenous WBCs (10 min). (C) A
significant number of stuck cells subsequently transmigrated into the node (45 min). (D) LFA-1 (CD11a) receptor blockade abrogates firm adhesion of L-selec-
tin–deficient WBCs delivered to HEV by platelets. The percentage of rolling cells that became firmly adherent for a mininum of 30 s (sticking fraction) was
determined in the presence or absence of LFA-1 mAb TIB 213. The data shown represent the mean 6 SD of seven venules in three animals. 
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vate and engage LFA-1. Moreover, in intravital microscopy
experiments where WBC and platelets were labeled with
different fluorescent dyes, we observed that platelets fre-
quently returned to the circulation after the WBCs they
had delivered became firmly adherent on the surface of an
HEV (Fig. 3). This suggests that platelets may be able to
participate repeatedly in the recruitment of leukocytes.
 
Activated Platelets Bind to Murine PBMC In Vitro.
 
Although
in situ labeling of circulating WBCs with rhodamine 6G al-
lows adequate visualization of nucleated cells in HEV, it
Figure 3. Lymphocyte delivery to
PLN of L-selectin–deficient mice
does not lead to platelet accumula-
tion in HEV. The micrographs show
a segment of the same HEV as in
Fig. 2 (blood flow from right to left)
10 min after injection of activated
human platelets. (A) A rolling aggre-
gate of bright 2979-bis-(2-carboxy-
ethyl)-5(and 6) carboxyfluorescein–
labeled platelets with a fainter
rhodamine 6G labeled WBC in their
midst can be seen (arrow). (B) 2 s
later, the platelet–WBC aggregate
has arrested firmly. Labeled platelets
are initially distributed randomly on
the surface of the stuck cell. (C)
Within 5 s after the WBC had be-
come stuck, platelets roll slowly
downstream across the body of the
adherent cell and eventually detach.
(D) 30 s later, all platelets have de-
tached and returned to the blood
stream, whereas the WBC remains
stuck at the HEV surface.
Figure 4. Activated human platelets bind to murine lymphocytes in suspension. Freshly isolated murine PBMCs were stained with FITC-conjugated
antibodies to TCR-a/b, B220, and Mac-1 to identify T cells, B cells, and monocytes, respectively. Activated human platelets were stained with PE-con-
jugated nonblocking antibody to P-selectin and then mixed with labeled PBMCs. (A) Identification of PBMC subsets from L-selectin–deficient mice ca-
pable of aggregating with platelets as determined by two-color flow cytometry. The quadrant markers were drawn based on appropriate negative controls
after gating separately for lymphocytes and monocytes. Double positive cells (upper right quadrant) represent the members of each subset capable of plate-
let binding. Events in the monocyte gate that show positive staining for P-selectin, but not Mac-1, are platelet aggregates (upper left quadrant). P-selec-
tin–dependent adhesion was evaluated by treating platelets with mAb WAPS 12.2 before and during incubation with PBMCs. Similar results were ob-
tained in wild-type mice. (B) Percentage of monocytes, T cells, and B cells of wild-type (1/1) and L-selectin-deficient (2/2) donor mice that interacted
with activated human platelets. The effect of P-selectin blocking mAb WAPS 12.2 (open bar) and nonblocking mAb S12 (dotted bars) was evaluated as de-
scribed in Materials and Methods. Bars reflect mean 6 SD of four independent experiments. 
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does not enable us to differentiate between the various leu-
kocyte populations that may participate in antigen-specific
immune responses. To identify the specific subsets of mu-
rine lymphocytes capable of interacting with human plate-
lets, PBMCs from wild-type or L-selectin–deficient mice
were preincubated with fluoresceinated mAbs detecting
specific antigens for either a/b T cells or B cells. Cells
were then incubated with activated human platelets prela-
beled with a nonblocking PE-conjugated P-selectin anti-
body, and platelet adhesion was quantified using two-color
flow cytometry (Fig. 4 a). For reference, platelet binding to
monocytes was also analyzed. Approximately half of all B
and T cells from both wild-type and L-selectin–deficient
mice formed aggregates with activated platelets (Fig. 4 b).
Over 98% of monocytes from either genotype also inter-
acted with platelets. The critical role of P-selectin in medi-
ating these interactions was determined by the ability of
mAb WAPS 12.2, but not by the nonblocking P-selectin
mAb S12, to significantly reduce the percentage of all
PBMC subsets bound by platelets. These data suggest that a
substantial fraction of circulating B and T lymphocytes can
associate with activated platelets in the blood stream.
Circulating Activated Platelets Reconstitute the CHS Response
in L-selectin–deficient Mice. Our results indicate that lym-
phocytes can use the platelet delivery mechanism to enter
the LN interstitium where they may encounter their cog-
nate antigen. Since this intravascular adhesion cascade does
not mandate a contribution by L-selectin, we tested whether
activated platelets in the circulation of L-selectin–deficient
mice can reconstitute the defect in CHS that has been pre-
viously described in these animals (7, 9). To address this is-
sue, the abdominal skin of mutant mice was exposed to
DNFB. Topically applied antigens are known to be taken
up primarily by dermal Langerhans’ cells which then mi-
grate to draining PLN where they present antigen to homed
lymphocytes. Our analysis has indicated that a peak in the
number of Langerhans’ cells is achieved 18–24 h after sen-
sitization (Catalina, M.D., and M.H. Siegelman, unpub-
lished data). To ensure optimal lymphocyte delivery to
PLN, mutant mice were repeatedly injected during this 6 h
time interval with a total number of 3 3 108 activated
platelets.
When ears of sham-treated mutant mice were rechal-
lenged with DNFB 5 d after sensitization, there was no de-
tectable CHS response (Fig. 5 a). Moreover, activated plate-
let treatment of sensitized wild-type mice did not enhance
the CHS response, which, in fact, was slightly lower in this
group (P ,0.05 versus sensitized wild-type without plate-
lets). In contrast, a dramatic CHS immune reaction was
elicited in sensitized mutant animals that had received acti-
vated platelets. The extent of ear swelling elicited with
DNFB in platelet-treated L-selectin–deficient mice was not
different from that elicited in sensitized wild-type mice irre-
spective of whether or not the latter had received activated
platelets. Pretreatment with P-selectin function-blocking mAb
WAPS 12.2, but not control mAb Hec 7 to the human
Figure 5. Circulating, activated platelets reconstitute CHS response in L-selectin–deficient mice. (A) Mice were sensitized to DNFB on day 0. CHS
was elicited at day 5, and the subsequent ear swelling response was measured 24 h later. 18 h after sensitization, some animals were injected intravenously
with TRAP-activated human platelets (3 3 108 in 3 ml over 6 h). Some L-selectin2/2 animals were also treated with either P-selectin mAb WAPS 12.2 or
CD31 mAb Hec 7. There was no significant difference between the response of L-selectin–deficient mice and wild-type mice which were elicited without
earlier sensitization (P .0.05). Ear swelling in sensitized wild-type animals with or without platelet infusion was highly significant (P ,0.001 versus elicit
only). In sensitized L-selectin2/2 mice, elicitation alone had no effect, whereas mutant mice that also received activated platelets displayed a dramatic
swelling response (P ,0.001) that was not different from that in sensitized wild-type animals with or without platelet treatment (P .0.05 versus both).
MAb Hec 7 had no significant effect (P .0.05 versus sensitized L-selectin2/2 receiving activated platelets only), whereas coinjection of platelets and MAb
WAPS12.2 abolished the delayed type hypersensitivity effect (P .0.05 versus both L-selectin2/2 groups without platelet infusion; P ,0.001 versus sensi-
tized, platelet-treated L-selectin2/2 animals; P ,0.01 versus sensitized, platelet plus MAb Hec 7–treated L-selectin2/2 animals). Data shown are mean 6 SD
from 4 to 11 mice in each group (5 measurements per ear before and after elicitation). (B) Antigen–specific T cells are present in PLN of L-selectin–defi-
cient mice only after treatment with activated platelets. Cells from mice sensitized 5 d earlier with DNFB were cultured for 36 h in the presence of
DNBS after which the cultures were pulsed with [3H]thymidine for 18 h. Each point represents the mean 6 SD of three separate mouse groups, with
each group consisting of pooled PLN from two mice. Each group was done in triplicate. Background proliferation was subtracted as previously described
(7). (C) Magnitude of CHS response in L-selectin–deficient mice receiving activated platelets correlates with the number of resident lymphocytes in
PLN. After eliciting a CHS response, six PLN per mouse (subiliac, axillary, and cervical) were harvested and the number of resident cells was counted
and correlated to the extent of the ear swelling. PLN were obtained from mice which had received no platelets (n 5 5), activated platelets (n 5 11), acti-
vated platelets pretreated with control mAb Hec 7 (n 5 4), or activated platelets pretreated with mAb WAPS 12.2 (n 5 5).202 Effect of Activated Platelets in L-selectin–deficient Mice
platelet antigen CD31, abolished the CHS response in
L-selectin–deficient mice. Since WAPS 12.2 neutralizes
human, but not murine, P-selectin, its inhibitory effect was
most likely due to blocking of platelet-mediated lympho-
cyte delivery to PLN during the sensitization phase, and
not a result of the inhibition of endothelial P-selectin–
mediated trafficking of effector cells during the elicitation
phase.
Antigen-specific T Cells Reside in the PLN of Platelet-treated
L-selectin–deficient Mice. To address whether the effect of
activated platelets on the CHS response was in the afferent
phase of the response, the presence of antigen-specific T
cells within draining PLN of sensitized mice was deter-
mined by the ability of DNBS to induce in vitro lympho-
cyte proliferation (Fig. 5 b). LN T cells isolated from sensi-
tized platelet-treated mutant mice proliferated in response
to the antigen comparably to those of wild-type animals,
whereas T cells from sensitized untreated L-selectin–defi-
cient animals did not proliferate at all. Furthermore, DNFB-
reactive T cells resided overwhelmingly in the PLN of both
L-selectin–deficient and wild-type mice after contact sensi-
tization, as no detectable proliferation was found in either
mesenteric LNs or spleens of these animals (reference 7 and
data not shown). The magnitude of the CHS response in
platelet-treated mutant animals directly correlated with the
number of resident lymphocytes in PLN, suggesting that
the number of antigen-specific T cell clones generated dur-
ing the sensitization phase determined the extent of the cu-
taneous reaction (Fig. 5 c).
Discussion
The observation that circulating, activated platelets can
promote not only adhesion of lymphocytes to HEV but
also reconstitute cell-mediated immunity in L-selectin–
deficient mice is important in several ways. It emphasizes
the mandatory requirement for lymphocyte localization to
PLN in a T cell–dependent immune response to a cutane-
ous antigen challenge. Moreover, it shows that L-selectin
per se is not the exclusive mechanism for lymphocyte
homing to PLN, at least in situations that lead to platelet
activation in the blood stream. Platelets, through surface
P-selectin, can provide a significant compensatory mecha-
nism for initiating lymphocyte–HEV interactions without
perturbing subsequent adhesion steps or later events such as
antigen recognition or lymphocyte migration and differenti-
ation, which are requisite for activation and clonal expan-
sion of immunocompetent T cells.
Our intravital microscopy observations of PLN–HEV in
L-selectin–deficient mice also suggest a second constitutive
adhesion pathway that can mediate rolling and perhaps lym-
phocyte recruitment to HEV. Although impaired in their
ability to interact with HEV, a minority of circulating L-selec-
tin–deficient WBCs (z12%) were still capable of rolling,
even when no activated platelets were injected. This low level
interaction was also observed in wild-type mice treated with
an L-selectin function-blocking antibody (10). Interestingly,
treatment of L-selectin–deficient animals with a P-selectin
function-blocking antibody reduced these residual lympho-
cyte–HEV interactions by z75% (Diacovo, T.G., and U.H.
von Andrian, unpublished data). However, it remains to be
determined whether this L-selectin–independent compo-
nent of rolling is mediated by endogenous P-selectin ex-
pressed on platelets, on endothelial cells, or on both.
Recent intravital microscopy studies of PLN–HEV in
wild-type mice have shown that stationary adhesion of
lymphocytes requires that L-selectin–mediated rolling is fol-
lowed by a G protein–coupled transmembrane signal that
results in the upregulation and subsequent engagement of
LFA-1 (6). Consistent with these observations, our present
results indicate that lymphocytes that become tethered to
HEV by platelets must also activate LFA-1 before they can
arrest. Although the precise mechanism(s) that control(s)
the physiologic modulation of LFA-1 activity remain(s) to
be defined, previous in vitro studies have implicated a role for
L-selectin (14–17). In fact, cross-linking of L-selectin on
naive, but not memory, T cells with either antibodies or
the HEV-derived L-selectin ligand GlyCAM-1, has been
reported to promote binding of LFA-1 to one of its coun-
terreceptors, ICAM (intercellular adhesion molecule)-1
(17). Signal transduction through PSGL-1 has been sug-
gested to mediate similar interactions in nonlymphoid leu-
kocytes (18–20). However, platelet-mediated cross-linking
of PSGL-1 on T cells did not appear to directly induce in-
tegrin activation; platelets bound to purified human pe-
ripheral blood T cells failed to convert rolling interactions
to firm adherence on PNAd coimmobilized with ICAM-1
in flow assays (Diacovo, T.G., and U.H. von Andrian, un-
published data). Similarly, surface-adherent platelet mono-
layers supported P-selectin–dependent T cell rolling, but
not firm adhesion, which has been shown to occur during
platelet interactions with neutrophils (21, 22). Thus, the
predominant contribution of platelets to lymphocyte traf-
ficking appears to be the facilitation of lymphocyte margin-
ation. Although our data do not exclude more subtle plate-
let-mediated effects that could potentially affect integrin
function on lymphocytes, it appears likely that additional
direct communication events between the passively teth-
ered lymphocyte and the vascular wall must occur to ini-
tiate the necessary downstream events that are required for
lymphocyte accumulation in lymphoid or chronically in-
flamed tissues.
Our results demonstrate that activated platelets can have
a profound effect on the formation of immunologic mem-
ory because they can significantly impact on the trafficking
pattern of lymphocytes. In particular, activated platelets are
likely to affect the migratory behavior of lymphocyte sub-
sets that express little or no L-selectin. This would include
populations such as activated and/or memory T cells,
which play a vital role in the initiation and maintenance of
inflammatory conditions. It is interesting in this context
that Th1, but not Th2, cells were recently found to acquire
the ability to interact with P-selectin, and this differential
ability was shown to be responsible for the preferential re-
cruitment of Th1 cells into inflamed skin and joints (23).
However, it appears that P-selectin binding activity is prob-203 Diacovo et al.
ably not restricted to this specific subset of T cells, as our
studies indicate that a much larger proportion (40–50%) of
both T and B cells can bind activated platelets, at least in
the murine system.
In humans, platelets may not only participate in hemostasis
but may similarly modulate immune function by virtue of
their ability to interact with both vascular endothelium and
circulating leukocytes. This dual function of platelets may
contribute to vascular pathology associated with chronic
inflammation. For instance, it is conceivable that platelets
may play a role in exacerbations of inflammatory bowel
disease, a pathological condition associated with an increase
in activated platelets in the systemic circulation (24), and
endothelial cell expression of PNAd in inflamed tissues (25).
Circulating, activated platelets may not only occlude the
intestinal microvasculature resulting in tissue infarction, but
also alter the homing pattern of T cells that play a pivotal
role in the pathogenesis of this and other chronic inflam-
matory diseases (26–28).
Clinical studies suggest that intravascular platelet activa-
tion may be a frequent occurrence in other settings as well.
For instance, elevated numbers of P-selectin–expressing plate-
lets have been detected in patients with diabetes mellitus,
and in healthy subjects at increased risk for developing in-
sulin-dependent diabetes mellitus (29, 30). In these settings
as well as in inflammatory bowel disease, activated platelets
may be encountered in the blood stream for extended peri-
ods of time. However, our experiments indicate that even
a single episode during which large numbers of activated
platelets are present in the systemic circulation can affect
lymphocyte trafficking. The total number of platelets that
were infused into L-selectin–deficient mice during a 6-h
period corresponded to z40–50% of the circulating plate-
let pool in each animal. This dose of activated platelets may
be clinically relevant since similar levels may be achieved as
a result of platelet transfusions to individuals with throm-
bocytopenia. At the time of transfusion, 15–50% of plate-
lets stored under blood bank conditions have been reported
to express P-selectin, depending on the method of isolation
and concentration in the transfusate (31, 32). Acute activa-
tion of circulating platelets can also occur as a consequence
of surgical procedures requiring cardiopulmonary bypass or
hemodialysis with bioincompatible filter membranes (33,
34). Thus, our studies simulate an extremely common clin-
ical condition that has not been examined so far with re-
gards to its consequences for a patient’s immune system.
We wish to thank Drs. E.C. Butcher, B. Coller, R.P. McEver, and W. Muller for supplying antibodies.
This work was supported by National Institutes of Health grants K08 HL-03361 (to T.G. Diacovo); HL-
54936, HL-48675, and HL-56949 (to U.H. von Andrian); and CA-56746 and HL-56746 (to M.H. Siegel-
man); and a grant from the Arthritis Foundation (to M.H. Siegelman). M.H. Siegelman is an Established In-
vestigator of the American Heart Association.
Address corrrespondence to Dr. Ulrich H. von Andrian, The Center for Blood Research, 200 Longwood Ave.,
Boston, MA 02115. Phone: 617-278-3130; Fax: 617-278-3190; E-mail: uva@cbr.med.harvard.edu
Received for publication 22 July 1997 and in revised form 6 November 1997.
References
1. Butcher, E.C., and L.J. Picker. 1996. Lymphocyte homing
and homeostasis. Science. 272:60–66.
2. Gallatin, W.M., I.L. Weissman, and E.C. Butcher. 1983. A
cell-surface molecule involved in organ-specific homing of
lymphocytes. Nature. 304:30–34.
3. Berg, E.L., M.K. Robinson, R.A. Warnock, and E.C.
Butcher. 1991. The human peripheral lymph node vascular
addressin is a ligand for LECAM-1, the peripheral lymph
node homing receptor. J. Cell Biol. 114:343–349.
4. Imai, Y., M.S. Singer, C. Fennie, L.A. Lasky, and S.D.
Rosen. 1991. Identification of a carbohydrate based endothe-
lial ligand for a lymphocyte homing receptor. J. Cell Biol.
113:1213–1221.
5. von Andrian, U.H. 1996. Intravital microscopy of the pe-
ripheral lymph node microcirculation in mice. Microcircula-
tion. 3:287–300.
6. Warnock, R.A., S. Askari, E.C. Butcher, and U.H. von An-
drian. 1998. Molecular mechanisms of lymphocyte homing
to peripheral lymph nodes. J. Exp. Med. 187:205–216.
7. Catalina, M.D., M.C. Carroll, H. Arizpe, A. Takashima, P.
Estess, and M.H. Siegelman. 1996. The route of antigen en-
try determines the requirement for L-selectin during immune
responses. J. Exp. Med. 184:2341–2351.
8. Arbonès, M.L., D.C. Ord, K. Ley, H. Ratech, C. Maynard-
Curry, G. Otten, and D.J. Capon. 1994. Lymphocyte hom-
ing and leukocyte rolling and migration are impaired in L-selec-
tin–deficient mice. Immunity. 1:247–260.
9. Tedder, T.F., D.A. Steeber, and P. Pizcueta. 1995. L-selec-
tin–deficient mice have impaired leukocyte recruitment into
inflammatory sites. J. Exp. Med. 181:2259–2264.
10. Diacovo, T.G., K.D. Puri, R.A. Warnock, T.A. Springer,
and U.H. von Andrian. 1996. Platelet-mediated lymphocyte
delivery to high endothelial venules. Science. 273:252–255.
11. Diacovo, T.G., A.R. de Fougerolles, D.F. Bainton, and T.A.
Springer. 1994. A functional integrin ligand on the surface of
platelets: intercellular adhesion molecule-2. J. Clin. Invest. 94:
1243–1251.
12. Lawrence, M.B., E.L. Berg, E.C. Butcher, and T.A.
Springer. 1995. Rolling of lymphocytes and neutrophils on
peripheral node addressin and subsequent arrest on ICAM-1
in shear flow. Eur. J. Immunol. 25:1025–1031.
13. McCaffery, P.J., and M.V. Berridge. 1986. Expression of the204 Effect of Activated Platelets in L-selectin–deficient Mice
leukocyte functional molecule (LFA-1) on mouse platelets.
Blood. 67:1757–1764.
14. Laudanna, C., G. Constantin, P. Baron, E. Scarpini, G. Scar-
lato, G. Cabrini, and C. Dechecchi. 1994. Sulfatides trigger
increase of cytosolic free calcium and enhanced expression of
tumor necrosis factor-a and interleukin-8 mRNA in human
neutrophils. J. Biol. Chem. 269:4021–4026.
15. Waddell, T.K., L. Fialkow, C.K. Chen, T.K. Kishimoto, and
G.P. Downey. 1994. Potentiation of the oxidative burst of
human neutrophils: a signaling role for L-selectin. J. Biol.
Chem. 269:18485–18491.
16. Brenner, B., E. Gulbins, K. Schlottmann, U. Koppenhoefer,
G.L. Busch, B. Walzog, M. Steinhausen, K.M. Coggeshall,
O. Linderkamp, and F. Lang. 1996. L-selectin activates the
Ras pathway via the tyrosine kinase p56lck. Proc. Natl. Acad.
Sci. USA. 93:15376–15381.
17. Hwang, S.T., M.S. Singer, P.A. Giblin, T.A. Yednock, K.B.
Bacon, S.I. Simon, and S.D. Rosen. 1996. GlyCam-1, a
physiologic ligand for L-selectin, activates b2 integrins on na-
ive peripheral lymphocytes. J. Exp. Med. 184:1343–1348.
18. Nagata, K., T. Tsuji, N. Todoroki, Y. Katagiri, K. Tanoue,
H. Yamazaki, N. Hanai. 1993. Activated platelets induce super-
oxide anion release by monocytes and neutrophils through
P-selectin (CD62). J. Immunol. 151:3267–3273.
19. Weyrich, A.S., M.R. Elstad, R.P. McEver, T.M. McIntyre,
K.L. Moore, J.H. Morrissey, and S.M. Prescott. 1996. Acti-
vated platelets signal chemokine synthesis by human mono-
cytes. J. Clin. Invest. 97:1525–1534.
20. Celi, A., G. Pellegrini, R. Lorenzet, A. De Blasi, N. Ready,
B.C. Furie, and B. Furie. P-selectin induces the expression of
tissue factor on monocytes. 1994. Proc. Natl. Acad. Sci. USA.
91:8767–8771.
21. Diacovo, T.G., S.J. Roth, J.M. Buccola, D.F. Bainton, and
T.A. Springer. 1996. Neutrophil rolling, arrest, and transmi-
gration across activated, surface-adherent platelets via sequen-
tial action of P-selectin and the b2-integrin CD11b/CD18.
Blood. 88:146–157.
22. Yeo, E.L., J. Sheppard, and I.A. Feuerstein. 1994. Role for
P-selectin and leukocyte activation in polymorphonuclear
cell adhesion to surface adherent activated platelets under phys-
iologic shear conditions (an injury vessel wall model). Blood.
83:2498–2507.
23. Astrup, F.D., D. Vestweber, E. Borges, M. Lohnig, R.
Brauer, U. Herz, H. Renz, R. Hallmann, A. Scheffold, A.
Radbruch, and A. Hamann. 1997. P- and E-selectin mediate
recruitment of T-helper-1 but not T-helper-2 cells into in-
flamed tissues. Nature. 385:81–83.
24. Collins, C.E., M.R. Cahill, A.C. Newland, and D.S. Ramp-
ton. 1994. Platelets circulate in an activated state in inflam-
matory bowel disease. Gastroenterology. 106:840–845.
25. Michie, S.A., P.R. Streeter, P.A. Bolt, E.C. Butcher, and L.J.
Picker. 1993. The human peripheral lymph node vascular ad-
dressin: an inducible endothelial antigen involved in lympho-
cyte homing. Am. J. Pathol. 143:1688–1698.
26. Christopher, S.P., C. Andreas, J.R. Turner, L.J. Saubermann,
A.C. Stevens, K. Bodinaku, C.O. Elson, S.P. Balk, and R.S.
Blumberg. 1996. Persistent clonal expansion of peripheral blood
CD41 lymphocytes in chronic inflammatory bowel disease. J.
Immunol. 157:3183–3191.
27. Konttinen, Y.T., V. Bergroth, D. Nordstrom, M. Segerberg-
Konttinen, K. Seppala, and M. Salaspuro. 1987. Lymphocyte
activation in vivo in the intestinal mucosa of patients with
Crohn’s disease. J. Clin. Lab. Immunol. 22:59–63.
28. Sauer, D., H. Sauer, and H. Fiebig. 1991. Circulating lym-
phocyte subpopulations in patients with Crohn’s disease. Gas-
troenterology. 51:27–32.
29. Tschoepe, D., P. Roesen, J. Esser, B. Schwippert, H.K.
Nieuwenhuis, B. Kehrel, and F.A. Gries. 1991. Large plate-
lets circulate in an activated state in diabetes mellitus. Semin.
Thromb. Hemostasis. 17:433–438.
30. Tschoepe, D., E. Driesch, B. Schwippert, and E.F. Lampeter.
1997. Activated platelets in subjects at increased risk of IDDM.
Diabetologia. 40:573–577.
31. Fijhneer, R., P.W. Modderman, and H. Veldman. 1990. De-
tection of platelet activation with monoclonal antibodies and
flow cytometry: changes during platelet storage. Transfusion.
30:20–25.
32. Rinder, H.M., M. Murphy, J.G. Mitchell, J. Stocks, K.A.
Aly, and R.S. Hillman. 1991. Progressive platelet activation
with storage: evidence for shortened survival of activated plate-
lets after transfusion. Transfusion. 31:409–414.
33. Rinder, C.S., J.L. Bonan, H.M. Rinder, J. Mathew, R.
Hines, and B.R. Smith. 1992. Cardiopulmonary bypass in-
duces leukocyte–platelet adhesion. Blood. 79:1201–1205.
34. Gawaz, M.P., S.K. Mujais, B. Schmidt, and H.J. Gurland. 1994.
Platelet-leukocyte aggregation during hemodialysis. Kidney Int.
46:489–495.